Overview

The Gene Technology Act 2000 was enacted to establish a legislative framework for the regulation of gene technology in Australia, addressing the need for careful oversight and management of activities involving genetically modified organisms to protect human health and the environment. The Act was introduced to ensure that gene technology is used in a way that minimises potential risks to human health and safety and the environment while promoting the potential benefits of gene technology. The enacting body responsible for this legislation is the Parliament of Australia. The policy objective of the Act is to balance the promotion of innovation and the benefits of gene technology with the need for stringent safety measures to protect public health and the environment. The Gene Technology Regulator is currently assessing an application from VRT Pharmaceutics Pty Ltd to conduct a clinical trial using a genetically modified Getah virus for cancer treatment. This trial, if approved, will be conducted under strict and controlled conditions at clinical trial sites in South Australia, involving up to 12 participants over a five-year period. The Regulator has prepared a Risk Assessment and Risk Management Plan (RARMP) for this application and is inviting written submissions from the public to consider the protection of human health and safety and the environment before making a decision on whether to issue the licence. Submissions should reference DIR 198 and should be received by 05 October 2023. Information regarding the RARMP and related details can be obtained via the Regulator’s website or by contacting the Office of the Gene Technology Regulator.

Scope and Application

The consultation on the clinical trial of a genetically modified alphavirus (Getah virus) for cancer treatment conducted by VRT Pharmaceutics Pty Ltd under the purview of the Gene Technology Act 2000 applies to the company's application to perform this trial in South Australia. The legislation targets the company's proposal to conduct a clinical trial of a genetically modified Getah virus for cancer treatment, and this involves both the company and the clinical trial sites in South Australia. The legislation extends to the assessment of the application by the Gene Technology Regulator, focusing on the protection of human health and safety and the environment. The Act’s jurisdictional reach is national, as it falls under the Commonwealth's responsibility for regulating gene technology. The exclusions or exemptions within the Act would be determined by the Regulator's review of the Risk Assessment and Risk Management Plan (RARMP) and the submissions received. The application of this Act may be extended or restricted through subordinate instruments such as regulations and guidelines, which provide further detail on the assessment process and requirements for such clinical trials. Submissions regarding this application are invited to ensure a thorough evaluation before any decision is made on issuing the licence.

Key Provisions

The primary focus of this legislation (C2023G00970) is the assessment of an application from VRT Pharmaceutics Pty Ltd to conduct a clinical trial of a genetically modified alphavirus, specifically the Getah virus, for cancer treatment (section 1). This trial is proposed to be conducted under strict and controlled conditions at clinical trial sites in South Australia, with a limited number of up to 12 participants over a period of five years (section 2). The Gene Technology Regulator has developed a Risk Assessment and Risk Management Plan (RARMP) to evaluate this application, and it encourages stakeholders to submit written comments regarding the protection of human health and safety, as well as the environment, before making a decision on whether to issue the licence (section 3). This consultation period is open until 05 October 2023, and all submissions must reference DIR 198. The obligations imposed by this legislation on the parties involved, particularly VRT Pharmaceutics Pty Ltd, include adhering to the strict conditions outlined in the clinical trial application and the RARMP. The company must ensure that all procedures are conducted under controlled conditions to mitigate any potential risks to human health and the environment. The company must also ensure that all trial participants are fully informed about the potential risks and benefits of the trial and obtain their informed consent. The Regulator, on the other hand, must review the application, assess the risks, and make a decision on whether to issue the licence based on the information provided and any comments received during the consultation period. In the event of a breach of the legislation, the Act provides for both civil and criminal penalties. The specific nature of the penalties will depend on the severity of the breach, the level of intent, and any harm caused as a result of the breach. For instance, if a participant is harmed due to a breach of the legislation, the responsible party could face criminal charges, which may result in fines or imprisonment. Similarly, if the breach results in significant harm to the environment, the responsible party could face hefty fines or imprisonment. The maximum penalties for these offences are not specified in the legislation, but they are likely to be significant, given the potential risks associated with the trial. The legislation also provides for civil penalties for breaches, which may include fines or other financial penalties. These penalties are intended to deter non-compliance and encourage parties to adhere to the strict conditions outlined in the legislation. The specific amount of the fine will depend on the nature and severity of the breach, as well as any harm caused as a result of the breach. In addition to the financial penalties, the legislation may also provide for other civil remedies, such as injunctions or orders to cease certain activities. These remedies are intended to prevent further breaches and to mitigate any harm caused by the breach. The legislation further emphasises the importance of protecting human health and the environment by providing for strict oversight and monitoring of the clinical trial. The Regulator is required to monitor the trial closely to ensure that all conditions are being met and that any risks are being managed effectively. The Regulator also has the power to inspect the trial sites, review the trial data, and take any necessary action to ensure compliance with the legislation. This oversight is intended to ensure that the trial is conducted in a safe and responsible manner and to minimise any potential risks to human health and the environment.